E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 9/9/2015 in the Prospect News Investment Grade Daily and Prospect News Liability Management Daily.

Roche begins tender offer for up to $1 billion of three note series

By Susanna Moon

Chicago, Sept. 9 – Roche Holdings, Inc. said it began a cash tender offer for up to $1 billion of three series of notes.

The company is tendering for $1,606,000,000 of 7% notes due 2039 and $2 billion of 6% notes due 2019 issued by Roche and guaranteed by Roche Holding Ltd. and $350 million of 5.25% senior notes due 2035 issued by Roche subsidiary Genentech, Inc.

Pricing will be set at 2 p.m. ET on Sept. 23 using a reference security plus a fixed spread as follows, with the notes listed in order of priority acceptance level:

• 7% notes due 2039 using the 3% U.S. Treasury notes due May 15, 2045 plus 105 basis points;

• 6% notes due 2019 using the 1.375% U.S. Treasury notes due Aug. 31, 2020 plus 30 bps; and

• 5.25% senior notes due 2035 using the 3% U.S. Treasury notes due May 15, 2045 plus 95 bps.

The total hypothetical purchase price for each $1,000 will be $1,448.02 for the 7% notes, $1,138.53 for the 6% notes and $1,180.75 for the 5.25% notes, with pricing set at 2 p.m. ET on Sept. 8 using an early settlement date of Sept. 24.

The total payout will include a $50.00 early tender premium per $1,000 of notes tendered by 5 p.m. ET on Sept. 22, the early tender date.

The tender offer will end at 11:59 p.m. ET on Oct. 6. Tendered notes may be withdrawn by 5 p.m. ET on Sept. 22.

The company also will pay accrued interest up to but excluding the settlement date of Sept. 24 for early tendered notes and Oct. 8 for remaining tenders.

Citigroup Global Markets Inc. (800 558-3745, 212 723-6106 or +44 20 7986 8969) is the dealer manager. Global Bondholder Services Corp. (866 470-4300, 212 430-3774 or info@gbsc-usa.com) is the depositary and information agent.

Roche is a Basel, Switzerland-based drug maker.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.